Cellular, Tissue and Gene Therapies
Advisory Committee Meeting
March 29, 2007
BIBLIOGRAPHY
Bernard, G, Reni, BI, et al:
Antigen-presenting cells 8015 (ProvenceŽ) in patients with androgen-dependent, biochemical
relapsed prostate cancer. Clin. Prostate Cancer 4(1):55-60,
2005.
Dagher, R, Li, N, et al:
Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent
hormone-refractory prostate cancer. Clin. Cancer Res.
10:8147-8151, 2004.
Gleason, DF, Histologic
grading of prostate cancer:: A perspective. Human
Pathology 23(3): 273-279, 1992.
IL-5 family
of receptors. Stem Cells
16:301-313, 1998.
Halabi, S, Small EJ, et al:
Prognostic model for predicting survival in men with hormone-refractory
metastatic prostate cancer. J. Clin. Oncology 21(7):1232-1237, 2003.
Montie, JE, Current
prognostic factors for prostate carcinoma. Cancer 72(2):341-344, 1996.
Smaletz, O,
Small, EJ, Fratesi, P, et al:
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded
dendritic cells. J. Clin. Oncology 20(23):3894-3903, 2000.
Small EJ, Schelhammer, PF, et
al: Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T
(APC8015) in patients with metastatic, asymptomatic hormone refractory prostate
cancer. J. Clin. Oncology 24(19):3089-3094, 2006.
Springer
TA, Adhesion receptors of the immune system. Nature 346:425-434, 1990.